Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

692 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E. Tolcher AW, et al. Among authors: gleave m. Clin Cancer Res. 2005 May 15;11(10):3854-61. doi: 10.1158/1078-0432.CCR-04-2145. Clin Cancer Res. 2005. PMID: 15897586 Clinical Trial.
Expression and nuclear localization of ErbB3 in prostate cancer.
Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Gleave M, Bégin LR, Mes-Masson AM, Saad F. Koumakpayi IH, et al. Among authors: gleave m. Clin Cancer Res. 2006 May 1;12(9):2730-7. doi: 10.1158/1078-0432.CCR-05-2242. Clin Cancer Res. 2006. PMID: 16675564
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS. Mostaghel EA, et al. Among authors: gleave me. Cancer Res. 2007 May 15;67(10):5033-41. doi: 10.1158/0008-5472.CAN-06-3332. Cancer Res. 2007. PMID: 17510436 Clinical Trial.
Insulin increases de novo steroidogenesis in prostate cancer cells.
Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, Herington A, Gleave ME, Pollak M, Nelson CC. Lubik AA, et al. Among authors: gleave me. Cancer Res. 2011 Sep 1;71(17):5754-64. doi: 10.1158/0008-5472.CAN-10-2470. Epub 2011 Jul 11. Cancer Res. 2011. PMID: 21747118 Free article.
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group. Saad F, et al. Among authors: gleave m. Clin Cancer Res. 2011 Sep 1;17(17):5765-73. doi: 10.1158/1078-0432.CCR-11-0859. Epub 2011 Jul 25. Clin Cancer Res. 2011. PMID: 21788353 Clinical Trial.
692 results